 Anti-Arrhythmia Agents
"Anti-Arrhythmia Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade.
| Descriptor ID |
D000889
|
| MeSH Number(s) |
D27.505.954.411.097
|
| Concept/Terms |
Anti-Arrhythmia Agents- Anti-Arrhythmia Agents
- Agents, Anti-Arrhythmia
- Anti Arrhythmia Agents
- Antiarrhythmic Drugs
- Drugs, Antiarrhythmic
- Antiarrhythmia Agents
- Agents, Antiarrhythmia
- Antiarrhythmia Drugs
- Drugs, Antiarrhythmia
- Anti-Arrhythmia Drugs
- Anti Arrhythmia Drugs
- Drugs, Anti-Arrhythmia
- Anti-Arrhythmics
- Anti Arrhythmics
Cardiac Depressants- Cardiac Depressants
- Depressants, Cardiac
- Myocardial Depressants
- Depressants, Myocardial
|
Below are MeSH descriptors whose meaning is more general than "Anti-Arrhythmia Agents".
Below are MeSH descriptors whose meaning is more specific than "Anti-Arrhythmia Agents".
This graph shows the total number of publications written about "Anti-Arrhythmia Agents" by people in this website by year, and whether "Anti-Arrhythmia Agents" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1980 | 1 | 0 | 1 | | 1984 | 9 | 0 | 9 | | 1985 | 8 | 2 | 10 | | 1986 | 5 | 1 | 6 | | 1987 | 5 | 0 | 5 | | 1991 | 0 | 1 | 1 | | 1992 | 0 | 2 | 2 | | 1993 | 1 | 1 | 2 | | 1994 | 2 | 1 | 3 | | 1995 | 0 | 2 | 2 | | 1996 | 1 | 1 | 2 | | 1997 | 0 | 1 | 1 | | 1998 | 2 | 0 | 2 | | 1999 | 1 | 1 | 2 | | 2000 | 1 | 1 | 2 | | 2002 | 3 | 1 | 4 | | 2003 | 1 | 0 | 1 | | 2004 | 1 | 1 | 2 | | 2005 | 4 | 1 | 5 | | 2006 | 2 | 0 | 2 | | 2007 | 4 | 2 | 6 | | 2008 | 2 | 0 | 2 | | 2009 | 2 | 1 | 3 | | 2010 | 4 | 0 | 4 | | 2011 | 1 | 0 | 1 | | 2014 | 1 | 1 | 2 | | 2015 | 1 | 0 | 1 | | 2016 | 1 | 1 | 2 | | 2017 | 0 | 1 | 1 | | 2018 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Anti-Arrhythmia Agents" by people in Profiles.
-
Madias C, Estes NAM. Class IC antiarrhythmic agents in structural heart disease: Is nothing CAST in stone? Heart Rhythm. 2018 02; 15(2):164-165.
-
Rogers PA, Bernard ML, Madias C, Thihalolipavan S, Mark Estes NA, Morin DP. Current Evidence-Based Understanding of the Epidemiology, Prevention, and Treatment of Atrial Fibrillation. Curr Probl Cardiol. 2018 Jun; 43(6):241-283.
-
Milan DJ, Saul JP, Somberg JC, Molnar J. Efficacy of Intravenous and Oral Sotalol in Pharmacologic Conversion of Atrial Fibrillation: A Systematic Review and Meta-Analysis. Cardiology. 2017; 136(1):52-60.
-
Somberg J, Molnar J. Adverse Reactions of Amiodarone on the Thyroid. Cardiology. 2016; 134(3):364-5.
-
Arif SA, Drury R, Ader P. Impact of Food and Drug Administration hepatotoxicity warning on prescribing and monitoring of dronedarone in a tertiary teaching hospital. Int J Pharm Pract. 2015 Dec; 23(6):456-60.
-
Zhang J, Zhou Q, Smith CD, Chen H, Tan Z, Chen B, Nani A, Wu G, Song LS, Fill M, Back TG, Chen SR. Non-ß-blocking R-carvedilol enantiomer suppresses Ca2+ waves and stress-induced ventricular tachyarrhythmia without lowering heart rate or blood pressure. Biochem J. 2015 Sep 01; 470(2):233-42.
-
Beaty EH, Ballany W, Trohman RG, Madias C. Ventricular tachycardia associated with radiation-induced cardiac sarcoma. Tex Heart Inst J. 2014 Dec; 41(6):620-5.
-
Pincus T, Sokka T, Cutolo M. The past versus the present, 1980-2004: reduction of mean initial low-dose, long-term glucocorticoid therapy in rheumatoid arthritis from 10.3 to 3.6 mg/day, concomitant with early methotrexate, with long-term effectiveness and safety of less than 5 mg/day. Neuroimmunomodulation. 2015; 22(1-2):89-103.
-
Zhou Q, Xiao J, Jiang D, Wang R, Vembaiyan K, Wang A, Smith CD, Xie C, Chen W, Zhang J, Tian X, Jones PP, Zhong X, Guo A, Chen H, Zhang L, Zhu W, Yang D, Li X, Chen J, Gillis AM, Duff HJ, Cheng H, Feldman AM, Song LS, Fill M, Back TG, Chen SR. Carvedilol and its new analogs suppress arrhythmogenic store overload-induced Ca2+ release. Nat Med. 2011 Jul 10; 17(8):1003-9.
-
Rosene ML, Wittmann G, Arrojo e Drigo R, Singru PS, Lechan RM, Bianco AC. Inhibition of the type 2 iodothyronine deiodinase underlies the elevated plasma TSH associated with amiodarone treatment. Endocrinology. 2010 Dec; 151(12):5961-70.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|